ESR1 and breast cancer: More recently, NOS2 expression was found to correlate directly with traditional predictive markers of survival including tumor grade, mutant P53, and tumor microvascularization, and predicted poor breast cancer specific survival at five and ten years in women with ER negative disease [28].